The biotech company Zymvol, a member of CATALONIA.HEALTH, has raised a seed funding of €3M. It was led by venture capital firms Faber Ventures (lead investor), Elaia Partners (existing pre-seed investor), and Übermorgen Ventures.
Since its founding in 2017, ZYMVOL has established itself as a leader in computational enzyme discovery and design. The company partners with R&D teams from some of the world’s largest firms to transform their production processes—boosting innovation and reducing environmental impact—through tailored enzymatic solutions.
Over the years, ZYMVOL has successfully completed more than 100 projects spanning diverse sectors, primarily in the pharmaceutical and chemical industries, collaborating with global clients such as Axplora, Medichem, and Sanofi. Thanks to the investment, the company is currently ready for new challenges. Its ambitious plan includes enhancing its experimental lab (located at the Barcelona Science Park); expanding its proprietary computational technology; increasing its sales and marketing team to reach new clients; and bringing its first custom-made enzyme kits to the market.
Comments